





































152-##_Other-1027-1-11-20211222.jpg


Volume 9- No. 5 2021

Educated Hand Publishing LLC 
“The Science Behind the Art” 
Volume 9 - No.5 2021 

 Anesthesia eJournal - Online
ISSN 2333-2611

Page 9

Hypotension and Bradycardia with Sugammadex Administration
Samantha Nicholson, BSN, RN, CCRN

Affiliation:
 Texas Christian University

Grant/Financial Support: 
None

Biographical data:  
Samantha Nicholson is a Registered Nurse pursuing her DNP in Nurse Anesthesia at Texas Christian University 

KEYWORDS:  sugammadex, Bridion®, reversal agent, adverse drug reaction

Abstract
The Food and Drug Administration (FDA) approved sugammadex for use as a reversal agent for nondepolarizing 
muscle relaxants.1 Sugammadex binds free molecules of muscle relaxant, specifically rocuronium and vecuronium, 
resulting in a rapid offset of neuromuscular blockade.2 When compared to the use of neostigmine and glycopyrrolate for 
reversal, sugammadex has shown to be faster and able to provide reversal for deeper blockades.2 However, this new drug 
is not without risks. Several case reports have been published describing profound hypotension and bradycardia after 
administration of sugammadex, with some cases progressing to asystole and death.1,3,4,5,6,7 This case report describes a 
patient who experienced a significant drop in cardiac output after being reversed with sugammadex. 

AEJ




